Rock Solid Nutrition, LLC 12/22/16
|
|
- Lindsey Fields
- 5 years ago
- Views:
Transcription
1 Rock Solid Nutrition, LLC 12/22/16 December 22, 2016 WARNING LETTER Kansas City District Office 8050 Marshall Drive - Suite 205 Lenexa, Kansas VIA UNITED PARCEL SERVICE OVERNIGHT MAIL RETURN RECEIPT REQUESTED Mr. Sean H. Loseke, Co-Owner Mr. Heath M. Murray, Co-Owner Rock Solid Nutrition, LLC 2424 S.156th Cir. Omaha, NE Reference CMS Case# Dear Mr. Loseke and Mr. Murray: On July 8, 2016 through July 12, 2016, the U.S. Food and Drug Administration (FDA) conducted an inspection of your dietary supplement facility located at 2424 S 156th Cir, Omaha, Nebraska. We collected product labels during the inspection for products you hold and distribute, including Whey Isolate (Cinnabun flavor), Pre-Pump (Massive Mango flavor), and Strength Test. Based on the inspection and a review of your product labeling, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act). You may find the Act and the Code of Federal Regulations (CFR) through links on FDA s home page at (
2 We have reviewed your written response dated July 26, 2016, submitted in response to the FDA Form 483 issued to you at the close of the inspection. We have included some detailed comments regarding your response below. Adulterated Dietary Supplements Your dietary supplement products are adulterated within the meaning of Section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] in that they have been prepared, packed or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulations for dietary supplements in Title 21 of the Code of Federal Regulations, Part 111 (21 CFR Part 111). During the July 8-12, 2016 inspection, our FDA investigator observed the following serious violations of the CGMP regulations for dietary supplements: 1. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, as required by 21 CFR Specifically, you have not established written procedures for quality control operations for ensuring the quality of incoming finished dietary supplement products, such as Pre-Pump, Whey Isolate, and Strength Test. Your written procedures for quality control operations must ensure that reserve samples are collected and held, all established specifications are met, master manufacturing records and batch production records are reviewed and approved, the dietary supplement is packaged and labeled as specified in the master manufacturing record, and returned dietary supplements are properly handled. (See 21 CFR part 111, subpart F.) Once you have established your written quality control procedures you must implement quality control operations, as required by 21 CFR During the inspection, you informed our investigator your firm is a distributor of your Rock Solid Nutrition brand dietary supplements and you have entered into agreements with manufacturers ( contract manufacturers ) to manufacture, package, and label your dietary supplement products. As a distributor that contracts with other manufacturers to manufacture, package, and label dietary supplements that your firm releases for distribution under your firm s brand name, FDA considers you to be ultimately responsible for the dietary supplements you introduce or deliver for introduction into interstate commerce. Although your firm may contract out dietary supplement manufacturing operations, it cannot, by the same token, contract out its ultimate responsibility to ensure the dietary supplements it places into commerce (or causes to be placed into commerce) are not adulterated for failure to comply with dietary supplement CGMP requirements (see United States v. Dotterweich, 320 U.S. 277, 284 (1943) (explaining that an offense can be committed under the Act by anyone who has "a responsible share in the furtherance of the transaction which the statute outlaws"); United States v. Park, 421 U.S. 658, 672 (1975) (holding that criminal liability under the Act does not turn on awareness of wrongdoing, and that "agents vested with the responsibility, and power commensurate with that responsibility, to devise whatever measures are necessary to ensure compliance with the Act" can be held accountable for violations of the Act)). In particular, the Act prohibits a person from introducing, delivering for introduction, or causing the delivery or introduction into interstate commerce of a dietary supplement that is adulterated under section 402
3 (g) for failure to comply with dietary supplement CGMP requirements (see 21 U.S.C. 342(g) and 331(a)). Thus, a firm that contracts with other firms to conduct certain dietary supplement manufacturing, packaging, and labeling operations for it is responsible for ensuring that the product is not adulterated for failure to comply with dietary supplement CGMP requirements, regardless of who actually performs the dietary supplement CGMP operations. As a distributor, you have an obligation to know what and how manufacturing activities are performed so your firm can make decisions related to whether your packaged and labeled dietary supplement products conform to established specifications and whether to approve and release the products for distribution. Your quality control personnel must approve for release, or reject, any packaged and labeled dietary supplement (including a repackaged or relabeled dietary supplement) for distribution. See 21 CFR (h). We have reviewed your response dated July 26, 2016 which included procedures for quality control within the Receiving and Returns procedures. However, we have determined these procedures are not adequate or specific enough to meet the requirements in 21 CFR because they did not address how quality control will ensure that reserve samples are collected and held, all established specifications are met, master manufacturing records and batch production records are reviewed and approved, and the dietary supplement is packaged and labeled as specified in the master manufacturing record. We also note the Returns procedure did not include the return document which is referenced in the procedure for our review. 2. You failed to establish and follow written procedures for holding and distributing operations, as required by 21 CFR Specifically, you did not have written procedures for holding and distributing operations of the dietary supplements you distribute. We have reviewed your response dated July 26, 2016 which included procedures for holding and distributing. However, we have determined your procedures are not adequate because your distributing procedures did not include details on the appropriate conditions for temperature, humidity, and light so the identity, purity, strength, and composition of the dietary supplements are not affected [21 CFR ], how you will hold reserve samples of dietary supplements [21 CFR ], how you will distribute dietary supplements under conditions that will protect the dietary supplements against contamination and deterioration [21 CFR ], and how product distribution records will be kept and maintained [21 CFR ]. Misbranded Dietary Supplements Your Whey Isolate (Cinnabun flavor), Pre-Pump (Massive Mango flavor), and Strength Test products are misbranded dietary supplement under section 403 of the Act [21 U.S.C. 343] because the products do not comply with the labeling requirements for dietary supplements. The inspection revealed the following violations of labeling requirements for dietary supplement: 1. Your Whey Isolate and Pre-Pump products are misbranded within the meaning of section 403 (q)(1)(a) of the Act [21 U.S.C. 34(q)(1)(A)] because the serving size declared on the label is incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b), 21 CFR (b) (1), and 21 CFR (b), Table 2. The serving size must also be expressed in a common household measure that is appropriate to the food.
4 Specifically, the directions of use suggest the consumer take 1-2 scoops, but the serving size for the Whey Isolate product lists 1 scoop, and the serving size for the Pre-Pump product lists 7.6 grams. The serving size listed should be 2 scoops. Additionally, the Pre-Pump serving size is not expressed in common household measure. It is unclear whether 7.6 grams of Pre-Pump is equivalent to 1 scoop or 2 scoops. For your Whey Isolate product, in addition to the serving size being incorrect, the number of servings noted along with the serving size of 32g does not correspond to the net contents of the product. 2. Your Whey Isolate, Pre-Pump, and Strength Test products are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR Specifically, Your Strength Test and Pre-Pump products fail to identify the source ingredient that supplies a dietary ingredient within the nutrition label in parentheses immediately following or indented beneath the name of a dietary ingredient and preceded by the words as or from or listed in an ingredient statement, as required by 21 CFR (d). For example, your Strength Test product lists the ingredient Vitamin D and your Pre-Pump product lists the ingredient theobromine, however, the source ingredients for these ingredients were not identified. Your Strength Test product lists both dietary ingredients with an established Reference Daily Intake (RDI) (e.g., Zinc, Vitamin D) and dietary ingredients for which FDA has not set a Daily Reference Value (DRV) or RDI (e.g., DHEA, Fenugreek, D-Aspartic Acid) as defined under 21 CFR (b)(2) and (b)(3), respectively. However, the label does not segregate the 21 CFR (b)(2) and (b)(3) dietary ingredients into separate sections of the supplement facts panel as required by 21 CFR (b)(3)(i). Additionally, heavy bars are required immediately after the listing of the last dietary ingredient required to be declared pursuant to 21 CFR (b)(2) and (b)(3), respectively (21 CFR (e)(6)(ii) and (iii)). Your Whey Isolate product fails to include a symbol in the % Daily Value column horizontal to the term Proprietary Protein Matrix blend, that links to the same symbol preceding the footnote Daily Value not established, as required by 21 CFR (c)(3). Your Whey Isolate product label incorrectly declares Vitamin A, C, and D at daily values less than 2 percent on the label. Any 21 CFR (b)(2)-ingredients that are not present, or are present in amounts that can be declared as zero in 21 CFR 101.9(c), shall not be declared (e.g., amounts corresponding to less than 2% of the RDI for vitamins and minerals), in accordance with 21 CFR (b)(2)(i). For your Strength Test product, the percentage DV for Vitamin D is incorrect. We note a product label may continue to use the 1993 RDIs for vitamins and minerals until July 26, 2017; or a product label may use the revised RDIs as published on May 27, Your Strength Test product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. 343(i)(2)] because the label fails to declare each ingredient as required by 21 CFR 101.4(a) and 21 CFR 101.4(g). For example, this product is manufactured into capsules, but the label fails to declare capsule ingredients and the term DHEA for the Strength Test product needs to be spelled out, as this is not the common or usual name of the ingredient.
5 4. Your Strength Test product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. 343(s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which the fenugreek ingredient is derived in accordance with 21 CFR 101.4(h). The above violations are not intended to be an all-inclusive list of violations at your facility. It is your responsibility to ensure all of your firm s products are in compliance with the Act and its implementing regulations. You should take prompt action to correct the violations cited in this letter and prevent their recurrence. Failure to promptly correct the violations may result in legal action without further notice including seizure or injunction. You should within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct violations including an explanation of each step taken to prevent the recurrence of violations and copies of supporting documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the date by which you will have completed the correction. In addition to the violations noted above, we have the following comments: We note that Other Ingredients list for the Pre-Pump product shall be located immediately below the nutrition label (Supplement Facts), which would be after the *Daily Value Not Established statement. You informed our investigator during the inspection that you provide design and content guidance to the company which produces the labels for your dietary supplement products. The labels are sent to your contact manufacturer, which applies them to the dietary supplement packaging. You are responsible for ensuring there are specifications for the labels and the labels conform to those specifications before they are used in the manufacture of your dietary supplements. Section 743 of the Act, 21 U.S.C. 379j-31, authorizes FDA to assess and collect fees to cover FDA's costs for certain activities, including re-inspection-related costs. A re-inspection is one or more inspections conducted subsequent to an inspection that identified non-compliance materially related to a food safety requirement of the Act, specifically to determine whether compliance has been achieved. Re-inspection-related costs means all expenses, including administrative expenses, incurred in connection with FDA's arranging, conducting, and evaluating the results of the re-inspection and assessing and collecting the re-inspection fees, 21 U.S.C. 379j-31(a)(2)(B). For a domestic facility, FDA will assess and collect fees for re-inspection-related costs from the responsible party for the domestic facility. The inspection noted in this letter identified noncompliance materially related to a food safety requirement of the Act. Accordingly, FDA may assess fees to cover any re-inspection- related costs. Your response should be sent to Andrew A. Hoopes, Compliance Officer, at 210 Walnut St., Suite 369, Des Moines, IA If you have any questions about this letter, please contact Mr. Hoopes at ext or him at andrew.hoopes@fda.hhs.gov. (mailto:andrew.hoopes@fda.hhs.gov) Sincerely, /S/ Cheryl A. Bigham -S District Director
6 Kansas City District More in 2016 (/ICECI/EnforcementActions/WarningLetters/2016/default.htm)
Reishi D. International, Inc. 2/6/18
Reishi D. International, Inc. 2/6/18 San Francisco District Office 1431 Harbor Bay Parkway Alameda, CA 94502-7070 Via UPS Overnight February 7, 2018 Mr. Zheng Xiong Li, CEO Reishi D. International, Inc.
More informationOptimum Bioenergy International Corp. 12/21/17
Optimum Bioenergy International Corp. 12/21/17 Office of Human and Animal Food Division 5 West 1431 Harbor Bay Parkway Alameda, CA 94502-7070 Sent Via UPS Signature Required WARNING LETTER December 21,
More informationLopez Gonzalez Santana Corporation dba Domel and dba Dermixx 8/28/17
Lopez Gonzalez Santana Corporation dba Domel and dba Dermixx 8/28/17 Office of Human and Animal Food Operations East Division IV Compliance Branch 466 Avenida Fernández Juncos San Juan, Puerto Rico 00901-3223
More informationTruVision Health LLC 11/30/17
TruVision Health LLC 11/30/17 Denver District Office 6 th Ave & Kipling St, Bldg 20 DFC P.O. Box 25087 Denver, CO 80225 November 30, 2017 WARNING LETTER Via UPS Overnight Ref: # HAFW4(DEN)-18-02-WL David
More informationGenetic Edge Compounds LLC 4/14/17
Genetic Edge Compounds LLC 4/14/17 April 14, 2017 2017 DAL WL 15 UPS Overnight Bradley N. Howard, Owner and CEO Genetic Edge Compounds, LLC (b)(6), (b)(7)(c) McKinney, Texas 75070 Mr. Howard: WARNING LETTER
More informationBetter Health Lab, Inc 2/18/15
U.S. Food and Drug Administration Protecting and Promoting Your Health Better Health Lab, Inc 2/18/15 Department of Health and Human Services Public Health Service Food and Drug Administration New Jersey
More informationEden s Answers Inc. and Sprigs Life Inc. 12/14/17
Eden s Answers Inc. and Sprigs Life Inc. 12/14/17 Cincinnati District Office 6751 Steger Drive Cincinnati, OH 45237 Telephone: (513) 679-2700 FAX: (513) 679-2772 December 14, 2017 VIA UPS Overnight Delivery
More informationSan Diego Compounding Pharmacy 9/25/17
San Diego Compounding Pharmacy 9/25/17 Division of Pharmaceutical Quality Operations IV 19701 Fairchild Road Los Angeles, CA 92612 WARNING LETTER VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED September
More informationTSDR Pharmacy Inc. dba brandmd Skin Care 11/9/17
TSDR Pharmacy Inc. dba brandmd Skin Care 11/9/17 Division of Pharmaceutical Quality Operations IV 19701 Fairchild, Irvine, CA 92612-2506 Telephone: 949-608-2900 Fax: 949-608-4417 WARNING LETTER VIA SIGNATURE
More informationStonegate Pharmacy LP 11/10/16
Stonegate Pharmacy LP 11/10/16 November 10, 2016 2017 DAL WL 03 WARNING LETTER UPS Overnight Rene F. Garza, Pharm.D., Chief Executive Officer Stonegate Pharmacy, LP 2501 W. William Cannon Drive, Suite
More informationPick and Pay Inc dba Cili Minerals 5/8/15
U.S. Food and Drug Administration Protecting and Promoting Your Health Pick and Pay Inc dba Cili Minerals 5/8/15 Department of Health and Human Services Public Health Service Food and Drug Administration
More informationPublic Health Service Food and Drug Administration Dallas District 4040 North Central Expressway Dallas, Texas
Department of Health and Human Services Public Health Service Food and Drug Administration Dallas District 4040 North Central Expressway Dallas, Texas 75204-3128 March 30, 2010 2010-DAL-WL-08 CERTIFIED
More informationSanapac Co., Inc. 3/24/17
Sanapac Co., Inc. 3/24/17 WARNING LETTER 17 PHI 07 PHILADELPHIA DISTRICT U.S. CUSTOMHOUSE 2ND AND CHESTNUT STREETS ROOM 900 PHILADELPHIA, PA 19106 TELEPHONE: 215 597 4390 VIA UNITED PARCEL SERVICE OVERNIGHT
More informationTown and Country Compounding and Consultation Services, LLC 10/17/17
Town and Country Compounding and Consultation Services, LLC 10/17/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973)
More informationMay 12, 2017 WARNING LETTER
U.S. Food and Drug Administration Seattle District Office 22215 26th Avenue SE, Suite 210 Bothell, Washington 98021 May 12, 2017 OVERNIGHT DELIVERY SIGNATURE REQUIRED In reply refer to WL SEA 17-14 Otto
More informationHieber's Pharmacy 12/5/17
Hieber's Pharmacy 12/5/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973) 331-4969 CERTIFIED MAIL RETURN RECEIPT REQUESTED
More informationTalon Compounding Pharmacy 10/3/17
Talon Compounding Pharmacy 10/3/17 Office of Pharmaceutical Quality Operations, Division II 4040 N. Central Expressway, Suite 300 Dallas, Texas 75204 October 3, 2017 CMS Case # 522630 VIA UPS EXPRESS WARNING
More informationOpiate Freedom Center 1/11/18
Opiate Freedom Center 1/11/18 UNITED STATES OF AMERICA DEPARTMENT OF HEALTH FEDERAL TRADE COMMISSION AND HUMAN SERVICES BUREAU OF CONSUMER FOOD AND DRUG ADMINISTRATION PROTECTION SILVER SPRING, MD 20993
More informationPublic Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA Telephone: 510/
Department of Health and Human Services Public Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA 94502-7070 Telephone: 510/337-6700 WARNING LETTER December
More informationSandoz Inc. 12-Aug-08
Sandoz Inc. 12-Aug-08 Department of Health and Human Services Public Health Service Food and Drug Administration Atlanta District Office 60 8th Street, N.E. Atlanta, Georgia 30309 August 12, 2008 VIA FEDERAL
More informationTobin's Royal Stag, Inc. dba Tobin Farms Velvet Antler 4/19/17
Tobin's Royal Stag, Inc. dba Tobin Farms Velvet Antler 4/19/17 UNITED PARCEL SERVICE OVERNIGHT DELIVERY April 19, 2017 Darrell Tobin Owner Tobin's Royal Stag, Inc. P.O. Box 108 Alna, ME 04535 0108 Dear
More informationOverview of Dietary Supplement GMP Inspection Trends Quality Session 6
Overview of Dietary Supplement GMP Inspection Trends Quality Session 6 Presented by: Dean R. Cirotta, MBA President & Chief Operating Officer EAS Consulting Group, LLC 1700 Diagonal Road, Suite 750 Alexandria,
More informationRaritan Pharmaceuticals, Inc. 6/20/17
Raritan Pharmaceuticals, Inc. 6/20/17 U.S. Food & Drug Administration Division of Pharmaceutical Quality Operations I New Jersey District 10 Waterview Boulevard, 3rd Floor Parsippany, NJ 07054 June 20,
More informationNYSW Beverage Brands 1/7/15
8/26/2015 2015 > NYSW Beverage Brands 1/7/15 U.S. Food and Drug Administration Protecting and Promoting Your Health NYSW Beverage Brands 1/7/15 SHARE (HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP? U=HTTP%3A%2F%2FWWW.FDA.GOV%2FICECI%2FENFORCEMENTACTIONS%2FWARNINGLETTERS%2F2015%2FUCM429530.HTM)
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations V-SAB Medical Labs,
More informationcgmp (21 CFR 111) Regulation and Compliance Overview
cgmp (21 CFR 111) Regulation and Compliance Overview Neogen Effective Compliance Seminar September 23, 2014 Michael McGuffin President, American Herbal Products Association mmcguffin@ahpa.org Regulation
More informationRed Mill Farms LLC 9/17/15
U.S. Food and Drug Administration Protecting and Promoting Your Health Red Mill Farms LLC 9/17/15 Department of Health and Human Services Public Health Service Food and Drug Administration PHILADELPHIA
More informationCERTIFIED MAIL RETURN RECEIPT REQUESTED. Esther Hernandez President United States Blood Bank, Inc NW 95th Avenue Miami, Florida
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 CERTIFIED MAIL RETURN RECEIPT REQUESTED Esther Hernandez President United States Blood Bank, Inc. 2400 NW 95th
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations P.A. Benjamin Manufacturing
More informationTheoriginalhcgdrops.com 11/28/11
Theoriginalhcgdrops.com 11/28/11 UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION BUREAU OF CONSUMER PROTECTION WASHINGTON, D.C. 20580 DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 9 Inspections, Compliance, Enforcement, and Criminal Investigations Phoenix Medical Devices, LLC 9/29/2009 Department of Health and Human Services Public Health Service Food and Drug Administration
More informationTeva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044
DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 090783 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs
More information4/26/2013. Libia Lugo Drug Specialist San Juan District Office Investigations Branch
Libia Lugo Drug Specialist San Juan District Office Investigations Branch The Food and Drug Administration (FDA) responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico,
More informationNestle Infant Nutrition 10/31/14
U.S. Food and Drug Administration Protecting and Promoting Your Health Nestle Infant Nutrition 10/31/14 OCT 31, 2014 Department of Health and Human Services Public Health Service Food and Drug Administration
More informationNOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 1401 Rockville Pike Rockville, MD 20852-1448 September 26, 2011 By Overnight Delivery Michael Dean Berger, M.D.
More informationNew England Compounding Center 04-Dec-06
New England Compounding Center 04-Dec-06 Department of Health and Human Services Public Health Service Food and Drug Administration New England District One Montvale Avenue Stoneham, Massachusetts 02180
More informationLong Life Unlimited 1/31/18
Long Life Unlimited 1/31/18 Cincinnati District Office 6751 Steger Drive Cincinnati, OH 45237 Telephone: (513) 679-2700 FAX: (513) 679-2772 WARNING LETTER 533282 January 31, 2018 VIA UPS Long Life Unlimited,
More informationRULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS
RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER 1140-17 DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS 1140-17-.01 Definitions 1140-17-.02 Purpose 1140-17-.03 Eligibility Criteria for Program Participation
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f J Dallas District 4040 North Central Expressway Dallas, Texas 75204-3145 Ref: 2004-DAL-WL-03 WARNING LETTER CERTIFIED MAIL RETURN
More informationPlanning For The FDA s 'Deeming Rule' For E- Cigarettes
Law360, New York (September 21, 2015, 3:39 PM ET) -- The 2009 Family Smoking Prevention and Tobacco Control Act (TCA)[1] gave the U.S. Food and Drug Administration the authority to oversee the manufacture,
More informationFood Labeling: Revision of the Nutrition and Supplement Facts Labels and Serving Sizes of
This document is scheduled to be published in the Federal Register on 10/02/2017 and available online at https://federalregister.gov/d/2017-21019, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationACTION: Notification; declaratory order; extension of compliance date.
This document is scheduled to be published in the Federal Register on 05/21/2018 and available online at https://federalregister.gov/d/2018-10714, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home > Inspections, Compliance, Enforcement, and Criminal Investigations > Enforcement Actions > Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Punjwani, Sohail S., M.D.
More informationSouthern California Section & Western Compendial Discussion Group
Association for Official and Analytical Chemists Southern California Section & Western Compendial Discussion Group October 6, 2011 Compliance Officer Bill Vitale, Food and Drug Administration Los Angeles
More informationGENERAL INFORMATION AND INSTRUCTIONS
NON-PARTICIPATING MANUFACTURER CERTIFICATION FOR LISTING ON OREGON DIRECTORY GENERAL INFORMATION AND INSTRUCTIONS Who is required to file this Certification? Any tobacco product manufacturer who is a non-participating
More informationAgency Information Collection Activities; Submission for Office of Management and Budget
This document is scheduled to be published in the Federal Register on 01/28/2016 and available online at http://federalregister.gov/a/2016-01690, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations A Nelson & Co.,
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations
More informationApril 30, By Electronic Mail
April 30, 2018 By Electronic Mail Dr. Scott Gottlieb, Commissioner Office of the Commissioner Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 CommissionerFDA@fda.hhs.gov
More informationEffective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products
Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Quick Facts Retailers that mix and prepare e-liquids or create or modify vaporizers
More informationFood Recalls: May 25, 2016 GREENBERG TRAURIG, LLP ATTORNEYS AT LAW Greenberg Traurig, LLP. All rights reserved.
Food Recalls: 2016 Greenberg Traurig, LLP. Attorneys at Law. All rights reserved. Greenberg Traurig is a trademark and trade name of Greenberg Traurig, LLP and Greenberg Traurig, P.A. This presentation
More informationResponsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA.
Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA (Laser Notice 51) Document issued on: May 27, 2001 U.S. Department of Health
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Burzynski Research Institute
More informationGuidance for Handling and Labeling
ECOCERT ICO Page 1/7 This guideline does not replace the current Regulation. It provides some explanations on main requirements for organic handling and labeling. To understand the complete organic requirements,
More informationAlignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference
Alignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference Donald Kautter US Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Food
More informationAs Introduced. 132nd General Assembly Regular Session H. B. No
132nd General Assembly Regular Session H. B. No. 560 2017-2018 Representative Lanese A B I L L To amend sections 923.41, 923.48, and 923.51 of the Revised Code to prohibit pet food from containing remains
More informationUse of Light, Mild, Low, or Similar Descriptors in the Label, Labeling, or Advertising of Tobacco Products
Guidance for Industry and FDA Staff Use of Light, Mild, Low, or Similar Descriptors in the Label, Labeling, or Advertising of Tobacco Products June 2010 For questions regarding this guidance, contact the
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW MEXICO ) ) ) ) ) ) ) ) ) INFORMATION. General Allegations. A. Introduction and Background
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW MEXICO UNITED STATES OF AMERICA, Plaintiff, vs. MOHAMED BASEL ASWAD, M.D., Defendant. CRIMINAL NO. 21 U.S.C. 331(a and 333(a(1: Introduction
More information2014 FDA/JIFSAN Food & Nutrition Webinar
2014 FDA/JIFSAN Food & Nutrition Webinar Medical Foods Shawne Suggs-Anderson, MMSc, _ RD Infant Formula and Medical Foods Staff ONLDS/CFSAN/FDA September 23, 2014 53 Main Objectives History What is a Medical
More informationDietary Supplement Health and Education Act of 1994 Public Law rd Congress
Dietary Supplement Health and Education Act of 1994 Public Law 103-417 103rd Congress An Act To amend the Federal Food, Drug, and Cosmetic Act to establish standards with respect to dietary supplements,
More informationMEDICINES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF FOOD/NUTRITIONAL/DIETARY SUPPLEMENTS IN THE GAMBIA
MEDICINES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF FOOD/NUTRITIONAL/DIETARY SUPPLEMENTS IN THE GAMBIA Document No.: MCA/NSG/17/11/01 Date of Adoption: 20 th January 2017 Date of Issue: 25 th July 2017
More informationO(K) SUMMARY. Mega'Gen Co., Ltd , Eupchun-Ri, Jain-Myun. Gyeongsan, Gyeongbuk South Korea Phone: , Fax:
EZ PLUS IMPLANT SYSTEM 13. 510O(K) SUMMARY Mega'Gen Co., Ltd. 114-8, Eupchun-Ri, Jain-Myun. Gyeongsan, Gyeongbuk South Korea Phone: 82-53-857-5770, Fax: 82-53-857-5432 510(K) Summary 510O(K) SUMMARY AND
More informationFDA and USDA Food Safety Regulations 101: Preventing Adulteration and Contamination
Food Law and Regulation Boot Camp November 15-16, 2016 FDA and USDA Food Safety Regulations 101: Preventing Adulteration and Contamination Justin J. Prochnow Shareholder, Greenberg Traurig Mollie Kober
More informationFood Fortification Regulations, 2016 (Gazetted on 24 October, 2016) ARRANGEMENT OF SECTIONS PART I PRELIMINARY
Statutory Instrument 120 of 2016 Food Fortification Regulations, 2016 (Gazetted on 24 October, 2016) [Cap 15:05 Section 1 Title 2 Interpretation ARRANGEMENT OF SECTIONS PART I PRELIMINARY 3 Inspection
More informationCase 2:18-cv JTF-dkv Document 1 Filed 09/25/18 Page 1 of 17 PageID 1 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TENNESSEE
Case 2:18-cv-02656-JTF-dkv Document 1 Filed 09/25/18 Page 1 of 17 PageID 1 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TENNESSEE ) UNITED STATES OF AMERICA, ) ) Civil No: 18-2656 Plaintiff,
More informationOverview of FDA Oversight and Enforcement on Drug Compounding
Overview of FDA Oversight and Enforcement on Drug Compounding Ruey Ju, Pharm.D., J.D. Senior Advisor for Compounding Compliance and Enforcement (Acting) Center for Drug Evaluation and Research Today s
More informationSUPPLEMENTS PACKAGING 101: ELEMENTS, PLACEMENT, LABELING AND CLAIMS. an ebook from ESHA Research
SUPPLEMENTS PACKAGING 101: ELEMENTS, PLACEMENT, LABELING AND CLAIMS an ebook from ESHA Research SUPPLEMENTS PACKAGING 101 2 TABLE OF CONTENTS Introduction... 3 Definition... 4 Packaging Basics... 5 What
More informationCase: 1:18-cv Document #: 1 Filed: 07/26/18 Page 1 of 19 PageID #:1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS
Case: 1:18-cv-05104 Document #: 1 Filed: 07/26/18 Page 1 of 19 PageID #:1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS UNITED STATES OF AMERICA, ) ) Plaintiff, ) ) v. ) ) Civil
More informationAbsonutrix 7/25/17. Atlanta District Office 60 8th Street NE Atlanta, GA July 25, 2017 VIA UPS
Absonutrix 7/25/17 Atlanta District Office 60 8th Street NE Atlanta, GA 30309 July 25, 2017 VIA UPS Himanshu Nautiyal, Owner Absonutrix, LLC 317 S. Westgate Drive Suite J Greensboro, NC 27407 WARNING LETTER
More informationKo0 -t. Exhibit 2 MAY 3 0? 510 (K) Summay. Company Name: Columbia Scientific Development, LLC 420 NW I Ith Ave., Suite 617 Portland, Oregon 97209
Ko0 -t Exhibit 2 MAY 3 0? 510 (K) Summay Company Name: Columbia Scientific Development, LLC 420 NW I Ith Ave., Suite 617 Portland, Oregon 97209 Contact: Stephen Shulman Phone: 734-663-0132 Fax: 734-663-1306
More informationRESULTS AT A GLANCE. FDA Oversight of Tobacco Manufacturing Establishments. HHS OIG Data Brief August 2017 OEI
HHS OIG Data Brief August 2017 OEI-01-15-00300 FDA Oversight of Tobacco Manufacturing Establishments RESULTS AT A GLANCE The Tobacco Control Act authorized FDA to regulate domestic tobacco manufacturers
More informationSUPPLIER INGREDIENT INFORMATION. 50 lb bag
SUPPLIER INGREDIENT INFORMATION CHOLMONDLEY'S ENGLISH MUFFIN LOAF BASE BRAND: ORTH 3206354-00 Cholmondley's English Muffin Loaf Base is a pre-blended, fully prepared, dry mix base for using in bread applications.
More informationMIAMI CHILDREN S HOSPITAL POLICY AND PROCEDURE
ISSUED BY: Research PAGE: 1 of 6 REPLACES POLICY DATED: EFFECTIVE DATE: 08/09/2012 DISTRIBUTION: Departmentwide APPROVED BY: Andrews, April (SVP/CECO), BOD Audit and Compliance Committee, Perdomo, Jose
More informationUse of Standards in Substantial Equivalence Determinations
Guidance for Industry and for FDA Staff Use of Standards in Substantial Equivalence Determinations Document issued on: March 12, 2000 U.S. Department Of Health And Human Services Food and Drug Administration
More informationNOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home > Inspections, Compliance, Enforcement, and Criminal Investigations > Enforcement Actions > Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Chawla, Sant P., M.D.
More informationLIVE INTERACTIVE YOUR DESKTOP. Food Recall Process. Cecilia M. Wolyniak Food and Drug Administration Office of Enforcement
LIVE INTERACTIVE LEARNING @ YOUR DESKTOP Food Recall Process Cecilia M. Wolyniak Food and Drug Administration Office of Enforcement Wednesday, December 9, 2009 LEGAL ISSUES Code of Federal Regulations
More informationGuidance for Industry
Guidance for Industry Dosage Delivery Devices for OTC Liquid Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationInspections, Compliance, Enforcement, and Criminal Investigations. Central Texas Regional Blood & Tissue Center 07-Nov-03
1 of 7 6/10/2009 2:20 PM Inspections, Compliance, Enforcement, and Criminal Investigations Department of Health and Human Services Public Health Service Food and Drug Administration Dallas District 4040
More informationARKANSAS STATE UNIVERSITY GOVERNING PRINCIPLES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH
ARKANSAS STATE UNIVERSITY GOVERNING PRINCIPLES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH 1.0 INTRODUCTION Arkansas State University (ASU) is committed to enhancing the growth of research and other
More informationAie Pharmaceuticals Inc 4/17/17
Aie Pharmaceuticals Inc 4/17/17 WARNING LETTER Los Angeles District 19701 Fairchild Road Los Angeles, CA 92612 UNITED PARCEL SERVICE SIGNATURE REQUIRED April 17, 2017 Dr. Magdi Youssef AIE Pharmaceuticals,
More informationFDLI ANNUAL CONFERENCE May 4, 2018
FDLI ANNUAL CONFERENCE May 4, 2018 DIETARY SUPPLEMENTS RETAILER ISSUES AND LIABILITY Jean Frydman, Partner, Chair FDA Practice Fox Rothschild, LLP FDA Concern is Safety Only DHSEA Act of 1994 Know what
More informationLEAF Marque Chain of Custody Self Assessment v1.0 Downloadable Copy B
LEAF Marque Chain of Custody Self Assessment v1.0 Downloadable Copy B This downloadable copy of the LEAF Marque Chain of Custody Self Assessment v1.0 is applicable to businesses that do not grow crops
More informationNOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)
More informationCIGARETTE FIRE SAFETY AND FIREFIGHTER PROTECTION ACT Act of Jul. 4, 2008, P.L. 518, No. 42 Cl. 35 AN ACT
CIGARETTE FIRE SAFETY AND FIREFIGHTER PROTECTION ACT Act of Jul. 4, 2008, P.L. 518, No. 42 Cl. 35 AN ACT Providing for testing standards for cigarette fire safety, for certification of compliance by manufacturers,
More informationko~ Tk (K) SUMMARY
ko~3367-3 13. 510(K) SUMMARY 7-Tk 1 92006 Mega'Gen Co., Ltd. 114-8, Eupchun-Ri, Jain-Myun, Gyeongsan, Gyeongbuk South Korea Phone: 82-53-857-5770, Fax: 82-53-857-5432 510(K) Summary 510O(K) SUMMARY AND
More informationFinal Rule for Preventive Controls for Animal Food
Final Rule for Preventive Controls for Animal Food http://www.fda.gov/fsma THE FUTURE IS NOW 1 Background Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food
More informationThe Marketing of a Food Ingredient Understanding a System that has Worked for 105 Years
The Marketing of a Food Ingredient Understanding a System that has Worked for 105 Years Gary L. Yingling Food Policy Impact December 2011 Copyright 2011 by K&L Gates LLP. All rights reserved. Brief Historical
More information(City, State, Zip Code)
This Partner Agency Agreement, dated this day of, 2015, is between COMMUNITY FOOD SHARE, INC. (CFS), whose address is 650 South Taylor Avenue, Louisville, CO 80027, and (Partner Agency) whose address is
More informationThe proposed rule is significant, and the requirements and exceptions are complex. Key provisions of the proposal are described below.
ADVISORY Food & Drug FDA ISSUES PROPOSED RULE TO ESTABLISH A UNIQUE DEVICE IDENTIFICATION SYSTEM FOR MEDICAL DEVICES July 16, 2012 On July 11, 2012, the Food and Drug Administration (FDA) published in
More informationPutting the Nutritional Supplement Industry to the Test: Looking for Transparency
Putting the Nutritional Supplement Industry to the Test: Looking for Transparency Frederick H. Fern @RickFern_HB ffern@harrisbeach.com Marina Plotkin @MarinaPlotkin_HB mplotkin@harrisbeach.com Putting
More informationU. AUG skeletal dynamics. 510(k) Summary of Safety and Effectiveness Skeletal Dynamics Geminus Volar Distal Radius Plate System
U. AUG 23 2011 00 skeletal dynamics 510(k) Summary of Safety and Effectiveness Skeletal Dynamics Geminus Volar Distal Radius Plate System Submitter: Skeletal Dynamics, LLC 6905 SW 67 Avenue Suite 201 Miami,
More informationToday is the Day - Final Regulations on Nutrition and Supplement Facts Labels and Serving Sizes Officially Published in the Federal Register
Today is the Day - Final Regulations on Nutrition and Supplement Facts Labels and Serving Sizes Officially Published in the Federal Register By: Carolina M. Wirth and Alyson L. Wooten PharmD Today, Friday,
More informationTaylor C. Wallace, PhD, CFS, FACN, March 22, 2018
Food Ingredients Taylor C. Wallace, PhD, CFS, FACN, March 22, 2018 Disclosures Think Healthy Group, Inc. George Mason University, Department of Nutrition and Food Studies Journal of the American College
More information7 Food and Drug Administration Via Federa 1 Express Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850
./ + I #~=% @fices.o # Jg DEPARTMENT OF HEACI H & HUMAN SERVICES - Public Health Service : %. % W(-I *4 +4~w.daa 7 Food and Drug Administration Via Federa 1 Express Center for Devices and JAN 25 2001 WARNING
More informationLOS ANGELES UNIFIED SCHOOL DISTRICT Policy Bulletin
TITLE: Drug, Alcohol and Tobacco-Free Workplace ROUTING All Schools and Offices NUMBER: All Employees ISSUER: Earl R. Perkins, Associate Superintendent Division of District Operations Dave Holmquist, General
More informationRULES. on Selection and Sale of Tobacco and Trade Terms with Suppliers CHAPTER I
RULES on Selection and Sale of Tobacco and Trade Terms with Suppliers CHAPTER I Article 1 Purpose The purpose of these Rules is to define and explain the product choices of the State Alcohol and Tobacco
More informationExhibit 2 RFQ Engagement Letter
Exhibit 2 RFQ 17-25 Engagement Letter The attached includes the 6 page proposed engagement letter to be used by HCC. ENGAGEMENT LETTER Dear: [Lead Counsel/Partner] We are pleased to inform you that your
More information